All In Biotech

Free tool

FAERS Monitor: Myalept

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125390 or its brand name (Myalept, Metreleptin). Reports on generic versions are filed under their own applications.

Reports

1,263

Serious

654

52% of reports

Hospitalization

374

Death reported

71

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue102
  • weight decreased93
  • therapy cessation92
  • blood glucose increased84
  • drug ineffective77
  • off label use68
  • therapy interrupted66
  • nausea61
  • blood triglycerides increased54
  • treatment noncompliance53
  • weight increased52
  • injection site pain48
  • maternal exposure during pregnancy48
  • decreased appetite47
  • glycosylated haemoglobin increased41

Reports by year received

View as table
YearReports
201415
201551
201695
201787
201889
2019140
2020203
202174
202293
2023111
2024134
202570
2026101

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,896 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood triglycerides increasedSignal5451.139.32,595
therapy cessationSignal9229.924.62,543
glycosylated haemoglobin increasedSignal4127.120.01,004
treatment noncomplianceSignal5316.112.4739
therapy interruptedSignal6615.412.2876
maternal exposure during pregnancySignal489.06.8333
blood glucose increasedSignal847.46.0465
product dose omission issueSignal1025.84.8404
weight decreasedSignal935.54.6347
weight increasedSignal523.93.0109
decreased appetiteSignal473.42.577
injection site painSignal482.62.047
off label use681.31.04
nausea611.31.04
drug ineffective771.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.